138,00 €
0,13 %
L&S, 24. Oktober, 22:54 Uhr
ISIN
US4576693075
Symbol
INSM
Berichte

Insmed Incorporated Aktie News

Neutral
PRNewsWire
3 Tage alt
—Insmed Leads Science Top Employers List for Fifth Year in a Row— BRIDGEWATER, N.J. , Oct. 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2025 Top Emplo...
Neutral
PRNewsWire
10 Tage alt
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic Inflammation —   BRINSUPRI Was Reviewed Under CHMP's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health and Therapeutic Innovation — BRIDGEWATER, N.J. , Oct. 17, 2025 /P...
Neutral
PRNewsWire
11 Tage alt
—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker— —Additional Analyses Will Highlight Efficacy, Symptom Reduction, and Biomarker Suppression in Patients with Non-Cystic Fibrosis Bronchiectasis— BRIDGEWATER, N.J. , Oct. 16, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to delive...
Neutral
PRNewsWire
12 Tage alt
BRIDGEWATER, N.J. , Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2025 financial results on Thursday, October 30, 2025.
Positiv
Seeking Alpha
26 Tage alt
Insmed remains a compelling biotech trade after Brinsupri's FDA approval for NCFB, with strong de-risking and significant market potential. Brinsupri's aggressive pricing and broad label could drive peak sales above $5 billion, with additional pipeline assets offering upside. M&A speculation is high, with INSM seen as a prime acquisition target for major pharma companies like GSK, AZN, and NVS.
Neutral
PRNewsWire
etwa ein Monat alt
—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session — —New  Analysis from Phase 3 ASPEN Trial Examines Efficacy and Safety of Brensocatib in Japanese Patients with Non-Cystic Fibrosis Bronchiectasis by Reduction of Exacerbation History—  BRIDGEWATER, N.J. , Sept. 22, 2025 /PRNewswire...
Neutral
Seeking Alpha
etwa 2 Monate alt
Insmed Incorporated (NASDAQ:INSM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst I'm Max Skor, a biotech analyst with Morgan Stanley, and I'm honored to have Will Lewis here, ...
Neutral
Seeking Alpha
etwa 2 Monate alt
Insmed Incorporated (NASDAQ:INSM ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:00 AM EDT Company Participants Sara Bonstein - Chief Financial Officer Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Thanks, everyone, for joining us.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen